| |
IC50(nM)
|
IC90(nM)
|
ΣFIC50a
|
ΣFIC90a
|
|---|
|
Tafenoquine – mirincamycin (n)
|
TQ
|
MIR
|
TQ
|
MIR
| | |
|---|
|
Field isolates (nb = 3)
|
2,962.85
|
2,357.12
|
9,027.36
|
15,653.18
|
0.56
|
0.50
|
|
3D7 (nc = 3)
|
1,348.48
|
19,539.36
|
2728.49
|
36,936.11
|
0.86
|
1.09
|
|
K1 (nc = 2)
|
1,076.23
|
24,736.61
|
5,271.96
|
39,284.24
|
0.88
|
1.03
|
|
All tested isolates (n = 8)
|
1,829.64
|
8,135.69
|
5,005.97
|
25,786.65
|
0.78
|
0.83
|
|
DHA – mirincamycin (n)
|
DHA
|
MIR
|
DHA
|
MIR
| | |
|
Field isolates (nb = 4)
|
3.23
|
1,067.34
|
13.0
|
20,101.72
|
0.81
|
0.69
|
|
3D7 (nc = 3)
|
1.90
|
16,995.36
|
4.78
|
34,781.20
|
0.86
|
0.85
|
|
K1 (nc = 2)
|
1.09
|
8,669.49
|
2.86
|
27,749.81
|
0.71
|
0.95
|
|
All tested isolates (n = 9)
|
2.12
|
4,276.94
|
6.65
|
25,925.12
|
0.80
|
0.83
|
|
Chloroquine – mirincamycin (nb)
|
CHL
|
MIR
|
CHL
|
MIR
| | |
|
Field isolates (nb = 2)
|
128.99
|
1,365.01
|
680.90
|
16,161.82
|
0.39
|
0.99
|
|
3D7 (nc = 4)
|
28.27
|
23,288.21
|
63.87
|
38,311.62
|
1,06
|
1.04
|
|
K1 (nc = 2)
|
651.93
|
18,869.50
|
1,174.69
|
36,535.66
|
0.95
|
0.99
|
|
All tested isolates (n = 8)
|
90.54
|
10,871.57
|
239.01
|
30,511.74
|
0.80
|
0.91
|
- aSynergy, <0.5; additivity, 0.5-2; antagonism,>2.
- bn, no. of fresh field isolates tested.
- cn, no. of repeats.
- Geometric mean IC50 and IC90 in nM for mirincamycin (MIR), tafenoquine (TQ), chloroquine (CHL) and dihydroartemisinin (DHA) as well as the sum of fractional inhibitory (ΣFIC) concentrations for P. falciparum field isolates and culture clones 3D7 (chloroquine-sensitive) and K1 (chloroquine-resistant) tested in checkerboards assays.
